InvestorsHub Logo
Followers 57
Posts 658
Boards Moderated 0
Alias Born 01/22/2023

Re: Single Stock post# 676275

Tuesday, 03/05/2024 9:01:52 AM

Tuesday, March 05, 2024 9:01:52 AM

Post# of 704141
AZ paid $6B for a partnership and the drug is approved by the US FDA. It is also approved in Scotland and Europe. NICE will eventually approve the drug IMO.

https://www.fiercepharma.com/pharma/nice-poised-reject-astrazeneca-daiichis-enhertu-her2-low-breast-cancer

https://www.fiercepharma.com/marketing/astrazeneca-daiichi-notch-fda-approval-for-breast-cancer-med-enhertu-third-line-setting

The cost of trastuzumab deruxtecan per 21-day cycle is $9,574 or $165,949 annually if patients remain on treatment for a full year
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News